Author name: Vincent Racaniello

I'm Professor of Microbiology and Immunology at Columbia University in New York. I run a research lab where we study poliovirus, rhinovirus, and other RNA viruses. I also love teaching about viruses - check out virology.ws, microbe.tv, or iTunes University for some of my offerings. I want to be Earth's virology professor.

TWiV 846: Beta was stirring, and now in a mouse

TWiV explores the impact of the intestinal virome on seroconversion after rotavirus vaccination, and implications of the ability of the SARS-CoV-2 beta variant to infect wild-type laboratory mice. Click arrow to playDownload TWiV 846 (61 MB .mp3, 102 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv

TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin

In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients. Hosts: Daniel Griffin and Vincent Racaniello Click arrow to playDownload TWiV 845 (58 MB .mp3, 48 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show …

TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin Read More »

TWiV 841: Unmasking immunity

TWiV provides an update on immunity to Omicron, results of a randomized controlled trial of face masks, and a study of correlates of protection against respiratory syncytial virus infection in the upper and lower respiratory tract of nonhuman primates. Click arrow to playDownload TWiV 841 (63 MB .mp3, 105 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv

TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin

In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long …

TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin Read More »

Scroll to Top